F-19 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY OF NEUROLEPTICS - THE 1ST INVIVO PHARMACOKINETICS OF TRIFLUOPERAZINE IN THE RAT-BRAIN AND THE 1ST INVIVO SPECTRUM OF FLUPHENAZINE IN THE HUMAN BRAIN

被引:26
作者
BARTELS, M
GUNTHER, U
ALBERT, K
MANN, K
SCHUFF, N
STUCKSTEDTE, H
机构
[1] PSYCHIAT HOSP WIESLOCH,WIESLOCH,GERMANY
[2] UNIV TUBINGEN,DEPT ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY
[3] BRUKER MED TECHN,RHEINSTETTEN,GERMANY
关键词
D O I
10.1016/0006-3223(91)90011-A
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In vivo F-19 nuclear magnetic resonance (F-19-NMR) spectroscopy measurements of trifluorinated neuroleptics (fluphenazine-FL and trifluoperazine-TFP) were made in rat brain as well as in human brain. Animal studies were performed at 4.7 Tesla. Using rats that have been treated with FL over a period of 3 weeks, a NMR signal could be detected within 8-15 min. Following a single intravenous injection of TFP, brain levels could be monitored with a time resolution of 30 min. The first F-19-NMR examination of a patient was made at 3.0 Tesla 1 day after injection of FL decanoate (37.5 mg) in the course of which a signal could be detected within 30 min. It is expected that F-19-NMR will become an important tool in psychopharmacological research.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 11 条
[1]  
Albert K, 1990, NMR Biomed, V3, P120, DOI 10.1002/nbm.1940030304
[2]  
ALBERT K, 1984, NMR TOMOGRAPHIE KLIN, P34
[3]  
[Anonymous], 1987, IWANAMIRIKAGAKUZITEN, V4, P783
[4]   F-19 MAGNETIC-RESONANCE IMAGING AND SPECTROSCOPY OF A FLUORINATED NEUROLEPTIC LIGAND - INVIVO AND INVITRO STUDIES [J].
ARNDT, DC ;
RATNER, AV ;
FAULL, KF ;
BARCHAS, JD ;
YOUNG, SW .
PSYCHIATRY RESEARCH, 1988, 25 (01) :73-79
[5]   FLUORINATED PSYCHOPHARMACOLOGICAL AGENTS - NONINVASIVE OBSERVATION BY F-19 NUCLEAR-MAGNETIC-RESONANCE [J].
BARTELS, M ;
ALBERT, K ;
KRUPPA, G ;
MANN, K ;
SCHROTH, G ;
TABARELLI, S ;
ZABEL, M .
PSYCHIATRY RESEARCH, 1986, 18 (03) :197-201
[6]  
BERKOWITZ BA, 1987, BIOPHYS J, V151, P681
[7]  
Hull W E, 1988, NMR Biomed, V1, P11, DOI 10.1002/nbm.1940010104
[8]  
JOERGENSEN A, 1986, PROGR DRUG METABOLIS, V9, P11
[9]  
KOMOROSKI RA, 1989, 8TH ANN M SOC MAGN R, V1, P444
[10]  
SCHMALZING G, 1977, DRUG METAB DISPOS, V5, P104